METASTATIC MELANOMA

This study tests a new treatment for people with stage IV melanoma that has spread to the brain. It combines a chemotherapy drug (temozolomide) with special immune cells (NK cells) from a healthy donor, designed to better attack cancer. The goal is to find the safest dose and see…

This study tests two drugs, cabozantinib and nivolumab, in people with advanced melanoma or head and neck cancer that hasn't responded to prior immunotherapy. The goal is to see if the combination can shrink or stabilize the cancer, and whether certain biomarkers in tumors can pr…

This study tests two drugs, binimetinib and encorafenib, in people with advanced melanoma that has spread to the brain. The drugs block enzymes that help cancer cells grow. The goal is to see if this combination can control the disease and improve survival. About 35 adults with a…

This study tests whether combining a personalized cell therapy (lifileucel) with an immunotherapy drug (pembrolizumab) works better than the drug alone for people with advanced melanoma that cannot be removed by surgery or has spread. About 670 adults with untreated melanoma will…

This study is for people with advanced melanoma whose cancer has started to grow again in a few spots despite treatment. Researchers are testing whether giving high-dose, focused radiation to those growing spots can delay further cancer spread. About 52 adults will receive this r…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the drug pembrolizumab, for advanced solid tumors like breast, lung, and skin cancers. The goal is to see if the combination is safe and helps the immune system attack cancer. Ab…

This study tests an experimental treatment called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has spread or come back. OBX-115 uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified in the lab to include a protein (IL…

This early-stage trial tests a new drug (IOV-3001) combined with an immune cell therapy (lifileucel) in adults with advanced melanoma that has stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can help control the disease. About…

This program offers AMTAGVI, a cell therapy, to people with advanced melanoma that cannot be removed by surgery or has spread. It is for patients who already had a batch made for commercial use, but that batch did not meet all quality standards—though it was still considered safe…

This early-stage trial tests a new treatment for people with advanced melanoma and other solid tumors that have spread. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack cancer, and give them back after a short course of chemotherapy. …

This study tests whether combining a liver-directed chemotherapy (HEPZATO KIT) with two immunotherapy drugs (nivolumab and relatlimab, together called Opdualag) is safe and effective for people with metastatic melanoma that has spread to the liver. About 15 participants who have …

This study tests if freezing part of a growing tumor (cryoablation) combined with two immunotherapy drugs (ipilimumab and nivolumab) can help control advanced melanoma that stopped responding to prior treatment. About 37 adults with unresectable melanoma will receive the combinat…

This study tests whether adding an experimental drug (GB1211) to the immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced melanoma or head and neck cancer. About 92 participants will receive either the combination or a placebo plus pembrolizu…

This study tests two different drug combinations in people with BRAF-V600 mutant melanoma that has spread to the brain. One group gets a targeted therapy (encorafenib + binimetinib) plus an immunotherapy (nivolumab), while the other gets two immunotherapies (ipilimumab + nivoluma…

This study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) with two anti-rejection medications (sirolimus and prednisone) can shrink or control advanced skin cancer in people who have had a kidney transplant. The goal is to treat the cancer while keepin…

This study is for people with melanoma or lung cancer that has spread to the lining of the brain and spinal cord (leptomeningeal disease). The treatment combines standard intravenous nivolumab with a new approach: injecting the drug directly into the spinal fluid. The goal is to …

This study tests whether combining two drugs—pembrolizumab (an immunotherapy) and aldesleukin (a protein that boosts immune cells)—can shrink tumors in people with advanced melanoma or kidney cancer. About 78 adults whose cancer has not responded to prior treatments will receive …

This early-phase study tests a new treatment for advanced melanoma that has stopped responding to standard immunotherapy. It combines memory-like natural killer cells (either from the patient or a donor) with two immunotherapy drugs, nivolumab and relatlimab. The main goal is to …

This early-stage study tests a new treatment called Adze1.C for adults with advanced melanoma that hasn't responded to standard therapies. Adze1.C is a specially designed virus that targets and kills cancer cells while also helping the immune system fight the tumor. The main goal…

This study tests a drug called avapritinib in people with advanced solid tumors that have certain genetic changes (CKIT or PDGFRA mutations). The goal is to see if the drug can shrink or control the cancer. About 50 adults with cancers like melanoma, sarcoma, or breast, lung, or …

This study tests whether a blood test that measures tumor DNA (ctDNA) can help doctors decide when to add a third immunotherapy drug (ipilimumab) for people with advanced melanoma who are already taking two others (nivolumab and relatlimab). About 90 adults with advanced or metas…

This study tests a new treatment called [212Pb]VMT01 for people with advanced melanoma that has not responded to prior therapies. The treatment delivers a powerful alpha-particle radiation directly to melanoma cells. It is given alone or with the immunotherapy drug nivolumab. The…

This study tests a new oral drug called STC-15, either alone or combined with toripalimab, in people with advanced solid tumors or certain sarcomas (leiomyosarcoma or liposarcoma) that have worsened after prior treatment. The goal is to see if the drug is safe and can shrink or c…

This early-stage study tests whether injecting a flu vaccine directly into melanoma tumors can shrink them or reduce cancer spread. About 36 adults with stage I to IV melanoma who have at least one tumor that can be felt or seen on ultrasound are eligible. The main goals are to c…

This early-stage trial is testing a personalized cell therapy called lifileucel for patients with advanced uveal melanoma, sarcoma, or liposarcoma. Doctors take a patient's own immune cells from a tumor, grow large numbers of them in a lab, and then infuse them back into the pati…

This early-stage study is testing whether adding a drug called nilotinib to standard melanoma treatments (dabrafenib/trametinib or encorafenib/binimetinib) is safe and tolerable for patients. It is for adults whose advanced, BRAF-mutated melanoma has stopped responding to or prog…

This study is testing an experimental drug called mirdametinib in people with advanced melanoma that has a specific genetic change (an NF1 mutation) and has continued to grow despite previous immunotherapy. The main goals are to see if the drug is safe and if it can slow or stop …

This study tests whether a short bout of cycling exercise right before immunotherapy (nivolumab and ipilimumab) is feasible and can boost the immune system's response in people with advanced melanoma. Researchers aim to see if this simple intervention increases cancer-fighting ce…

This study tests whether giving radiation in three smaller doses (fractionated SRS) is better than the standard single large dose (SRS) for treating cancer that has spread to the brain. About 269 adults with certain cancers (lung, breast, melanoma, kidney, or gastrointestinal) wi…

This study looks at whether getting immunotherapy in the morning or afternoon changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect the immune system's response. About 160 adults with certain ca…

This study is for adults with advanced cancers like lung, liver, or skin cancer who are eligible for treatment with the drug atezolizumab. Researchers want to see if giving a lower dose less often can still control the cancer while causing fewer side effects. Participants will st…

This study tests whether freezing cancer spots in the bone (cryoablation) before giving radiation therapy works better than radiation alone for pain relief. About 40 adults with cancer that has spread to the bones will take part. The goal is to see if the combination reduces pain…

This study looks at how T cells change in people with advanced melanoma, lung, or other cancers during anti-PD-1 immunotherapy. Researchers will measure specific markers in blood samples to see if they can predict treatment response or resistance. The goal is to better understand…

This study aims to create an artificial intelligence tool that analyzes photos of skin damage around a melanoma scar to predict whether a patient will respond to anti-PD-1 immunotherapy. Researchers will enroll 700 adults with advanced melanoma or other skin cancers. The goal is …

This study watches 50 people who already received replimune immunotherapy for cancers like melanoma or liver cancer. The goal is to see if any side effects show up years later. No new treatment is given—just regular checkups for 5 years. It helps doctors understand the long-term …

This study looks at how effective first-line immunotherapy is for people with metastatic melanoma in Slovenia. Researchers will track treatment response and safety, and analyze blood, stool, and body fluids to find markers that predict who benefits most. The goal is to improve pe…

This study is looking at how effective immunotherapy is as a first treatment for metastatic melanoma that has spread. Researchers will check if a marker called PD-L1, found in tumors and blood, can help predict who will respond well. About 100 adults with advanced melanoma will t…